Sponsors (11)
The bill reduces national-security and IP risks from digital synthetic genetic sequences by adding export controls and licensing targeted at high‑risk foreign recipients, but does so at the cost of higher compliance burdens, slower international scientific and commercial collaboration, and some risk to medical research and academic exchange.
Scientists, biotech and tech firms, and the public are less likely to have sensitive synthetic genetic sequences and related IP used by hostile foreign actors because the bill imposes tighter export controls and licensing for digital genetic sequence exports.
U.S. biotech companies and researchers retain stronger protection for proprietary designs and long-term commercial value because export limits reduce the risk of foreign theft of biotech IP.
Scientists and students can continue routine, previously exempted types of international collaboration because the bill preserves the existing EAR §734.3(b) exemption for certain materials and exchanges.
U.S. researchers, tech workers, and biotech firms will face higher compliance costs, licensing delays, and administrative burdens that can slow exports of design files and hinder routine international research and commercial transactions.
Patients and public-health research programs could be harmed if controls limit legitimate sharing of sequence data and collaboration that speed medical research and outbreak response.
Vague or ambiguous terms (e.g., scope of 'digital sequence' or what counts as 'synthetic' modification) create legal uncertainty that chills academic and industry collaboration and data-sharing.
Based on analysis of 3 sections of legislative text.
Requires the Commerce Secretary to impose, within one year, a licensing requirement for exports, reexports, or in‑country transfers of any digital file that encodes human‑ or AI‑designed synthetic DNA or RNA to designated foreign entities of concern. The rule uses the Export Control Reform Act framework and exempts information already excluded by the Export Administration Regulations (EAR §734.3(b)). Defines key terms for the new control: what counts as a "digital sequence," what is a "synthetic DNA or RNA," and which foreign persons and governments qualify as entities of concern (tied to an existing statutory list of countries of concern). The change targets data transfers rather than physical biological materials and is intended to limit foreign access to sequence data that could reveal designs, proprietary research, or enable strategic/dual‑use technology development.
Introduced December 11, 2025 by Warren Davidson · Last progress December 11, 2025